AssetMark Inc’s Organogenesis Holdings ORGO Stock Holding History

AssetMark Inc’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4	Closed	-$11	–	2196
2024 Q1	$11	Buy	+4	New	+$14	﹤0.01%	1906

Other funds holding ORGO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AssetMark Inc's ORGO Position: Q2 2024 in Review

AssetMark Inc sold out of Organogenesis Holdings (ORGO) in Q2 2024, closing a stake of 4 shares — an estimated $11 sold.

AssetMark Inc first reported a position in ORGO in Q1 2024 and held it in 1 quarter. The position peaked at $11 in Q1 2024. 115 funds tracked by Wall St. Rank hold ORGO as of Q2 2024.

AssetMark Inc reported no remaining Organogenesis Holdings position as of Q2 2024 after selling out during the quarter.
AssetMark Inc sold 4 Organogenesis Holdings shares in Q2 2024, an estimated $11.
AssetMark Inc first reported a position in Organogenesis Holdings in Q1 2024 and held it in 1 quarter.
AssetMark Inc's Organogenesis Holdings position peaked at $11 in Q1 2024.
115 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2024.

Based on AssetMark Inc's 13F filing for Q2 2024, filed 13 Aug 2024.